Data gathered: July 27
Alternative Data for Catalyst Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 79 | Sign up | Sign up | Sign up |
| Google Trends | 28 | Sign up | Sign up | Sign up |
| Patents | 2 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 9 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,897 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,590 | Sign up | Sign up | Sign up |
| Twitter Followers | 900 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 40 | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
| Price | $17.59 |
| Target Price | Sign up |
| Volume | 645,100 |
| Market Cap | $2.05B |
| Year Range | $13.18 - $17.59 |
| Dividend Yield | 0% |
| PE Ratio | 31.02 |
| Earnings Date | August 7 '24 |
| Industry | Biotechnology |
In the news
 |
Ameritas Investment Partners Inc. Grows Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)July 26 - ETF Daily News |
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaJuly 24 - GlobeNewswire |
|
Catalyst Pharmaceuticals enters exclusive agreement with Kye PharmaceuticalsJuly 23 - Thefly.com |
|
|
US Bancorp DE Has $773,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)July 23 - ETF Daily News |
|
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Swiss National BankJuly 23 - ETF Daily News |
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024July 22 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 99M | 69M | 30M | 23M | 36M | 0.190 |
| Q4 '23 | 111M | 67M | 44M | 35M | 51M | 0.310 |
| Q3 '23 | 103M | 48M | 55M | -31M | -29M | -0.290 |
| Q2 '23 | 100M | 40M | 59M | 38M | 55M | 0.530 |
| Q1 '23 | 85M | 46M | 39M | 30M | 42M | 0.260 |
Insider Transactions View All
| Del Carmen Jeffrey filed to sell 18,427 shares at $16.1. June 11 '24 |
| INGENITO GARY filed to sell 51,391 shares at $16.2. June 7 '24 |
| Daly Richard J filed to sell 234,824 shares at $16. June 5 '24 |
| Tierney David S filed to sell 348,874 shares at $15.7. April 10 '24 |
Similar companies
Read more about Catalyst Pharmaceuticals (CPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Catalyst Pharmaceuticals?
The Market Cap of Catalyst Pharmaceuticals is $2.05B.
What is Catalyst Pharmaceuticals' PE Ratio?
As of today, Catalyst Pharmaceuticals' PE (Price to Earnings) ratio is 31.02.
When does Catalyst Pharmaceuticals report earnings?
Catalyst Pharmaceuticals will report its next earnings on August 7 '24.
What is the current stock price of Catalyst Pharmaceuticals?
Currently, the price of one share of Catalyst Pharmaceuticals stock is $17.59.
How can I analyze the CPRX stock price chart for investment decisions?
The CPRX stock price chart above provides a comprehensive visual representation of Catalyst Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalyst Pharmaceuticals shares. Our platform offers an up-to-date CPRX stock price chart, along with technical data analysis and alternative data insights.
Does CPRX offer dividends to its shareholders?
As of our latest update, Catalyst Pharmaceuticals (CPRX) does not offer dividends to its shareholders. Investors interested in Catalyst Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Catalyst Pharmaceuticals?
Some of the similar stocks of Catalyst Pharmaceuticals are Amgen, Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.